These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32390704)

  • 21. Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.
    Mahmud N; John B; Taddei TH; Goldberg DS
    Clin Transplant; 2019 Jul; 33(7):e13634. PubMed ID: 31177570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum levels of ferritin and transferrin serve as prognostic factors for mortality and survival in patients with end-stage liver disease: A propensity score-matched cohort study.
    Meier JA; Bokemeyer A; Cordes F; Fuhrmann V; Schmidt H; Hüsing-Kabar A; Kabar I
    United European Gastroenterol J; 2020 Apr; 8(3):332-339. PubMed ID: 32213016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measurement of liver iron concentration by superconducting quantum interference device biomagnetic liver susceptometry validates serum ferritin as prognostic parameter for allogeneic stem cell transplantation.
    Jacobi N; Herich L
    Eur J Haematol; 2016 Oct; 97(4):336-41. PubMed ID: 26800433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic and cardiac iron overload among patients with end-stage liver disease referred for liver transplantation.
    O'Glasser AY; Scott DL; Corless CL; Zaman A; Sasaki A; Gopal DV; Rayhill SC; Orloff SL; Ham JM; Rabkin JM; Flora K; Davies CH; Broberg CS; Schwartz JM
    Clin Transplant; 2010; 24(5):643-51. PubMed ID: 19925473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT).
    Hilken A; Langebrake C; Wolschke C; Kersten JF; Rohde H; Nielsen P; Kröger N
    Ann Hematol; 2017 Aug; 96(8):1379-1388. PubMed ID: 28585071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative serum ferritin is an independent prognostic factor for liver cancer after hepatectomy.
    Wu SJ; Zhang ZZ; Cheng NS; Xiong XZ; Yang L
    Surg Oncol; 2019 Jun; 29():159-167. PubMed ID: 31196483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of iron overload with infectious complications in liver transplant recipients: a systematic review and meta-analysis.
    Zhang J; Yan B; Shi X
    J Int Med Res; 2024 Mar; 52(3):3000605241232920. PubMed ID: 38518199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive Models of Hepatocellular Carcinoma Recurrence After Liver Transplantation.
    Sánchez Segura J; León Díaz FJ; Pérez Reyes M; Cabañó Muñoz D; Sánchez Pérez B; Pérez Daga JA; Montiel Casado C; Santoyo Santoyo J
    Transplant Proc; 2020 Mar; 52(2):546-548. PubMed ID: 32037068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower mean platelet volume is a risk indicator of hepatocellular carcinoma recurrence following liver transplantation.
    Zhang AB; Zhang ZH; Zhang J; Lin BY; Geng L; Yang Z; Feng XN; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):223-227. PubMed ID: 31056483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-liver transplant renal dysfunction and association with post-transplant end-stage renal disease: A single-center examination of updated UNOS recommendations.
    Chauhan K; Azzi Y; Faddoul G; Liriano-Ward L; Chang P; Nadkarni G; Delaney V; Ames S; Debnath N; Singh N; Sehgal V; Di Boccardo G; Garzon F; Nair V; Kent R; Lerner S; Coca S; Shapiro R; Florman S; Schiano T; Menon MC
    Clin Transplant; 2018 Dec; 32(12):e13428. PubMed ID: 30338873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.
    Gordon FD; Goldberg DS; Goodrich NP; Lok AS; Verna EC; Selzner N; Stravitz RT; Merion RM
    Liver Transpl; 2016 Sep; 22(9):1214-22. PubMed ID: 27339253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk Factors for Post-Transplant Death in Donation after Circulatory Death Liver Transplantation.
    Liu S; Miao J; Shi X; Wu Y; Jiang C; Zhu X; Wu X; Ding Y; Xu Q
    J Invest Surg; 2018 Oct; 31(5):393-401. PubMed ID: 28829664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series.
    Sapisochin G; Goldaracena N; Astete S; Laurence JM; Davidson D; Rafael E; Castells L; Sandroussi C; Bilbao I; Dopazo C; Grant DR; Lázaro JL; Caralt M; Ghanekar A; McGilvray ID; Lilly L; Cattral MS; Selzner M; Charco R; Greig PD
    Ann Surg Oncol; 2015 Jul; 22(7):2286-94. PubMed ID: 25472651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
    Kwong AJ; Lai JC; Dodge JL; Roberts JP
    Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.
    Lai Q; Inostroza M; Rico Juri JM; Goffette P; Lerut J
    HPB (Oxford); 2015 Dec; 17(12):1085-95. PubMed ID: 26373980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis.
    Lee MW; Raman SS; Asvadi NH; Siripongsakun S; Hicks RM; Chen J; Worakitsitisatorn A; McWilliams J; Tong MJ; Finn RS; Agopian VG; Busuttil RW; Lu DSK
    Hepatology; 2017 Jun; 65(6):1979-1990. PubMed ID: 28170115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation.
    Han S; Lee S; Yang JD; Leise MD; Ahn JH; Kim S; Jung K; Gwak MS; Kim GS; Ko JS
    Liver Transpl; 2018 Jan; 24(1):44-55. PubMed ID: 29024412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.